NO20092433L - Anvendelse av beta-laktamase - Google Patents

Anvendelse av beta-laktamase

Info

Publication number
NO20092433L
NO20092433L NO20092433A NO20092433A NO20092433L NO 20092433 L NO20092433 L NO 20092433L NO 20092433 A NO20092433 A NO 20092433A NO 20092433 A NO20092433 A NO 20092433A NO 20092433 L NO20092433 L NO 20092433L
Authority
NO
Norway
Prior art keywords
beta
lactamase
antibiotic
class
combination
Prior art date
Application number
NO20092433A
Other languages
English (en)
Inventor
Pertti Koski
Tapio Korkolainen
Kristiina Raatesalmi
Original Assignee
Ipsat Therapies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsat Therapies Oy filed Critical Ipsat Therapies Oy
Publication of NO20092433L publication Critical patent/NO20092433L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Klasse A beta-laktamase kan anvendes for å redusere bivirkninger i tarmen forbundet med antibiotikabehandling med en kombinasjon av beta- laktamantibiotikum og beta-laktamaseinhibitor.
NO20092433A 2006-11-28 2009-06-26 Anvendelse av beta-laktamase NO20092433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20065757A FI119678B (fi) 2006-11-28 2006-11-28 Beta-laktamaasin käyttö
PCT/FI2007/050627 WO2008065247A1 (en) 2006-11-28 2007-11-21 Use of beta-lactamase

Publications (1)

Publication Number Publication Date
NO20092433L true NO20092433L (no) 2009-06-26

Family

ID=37482569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092433A NO20092433L (no) 2006-11-28 2009-06-26 Anvendelse av beta-laktamase

Country Status (12)

Country Link
US (1) US20090311234A1 (no)
EP (1) EP2086570A1 (no)
JP (1) JP2010511020A (no)
KR (1) KR20090085122A (no)
CN (1) CN101563099A (no)
AU (1) AU2007327472A1 (no)
BR (1) BRPI0718880A2 (no)
CA (1) CA2670440A1 (no)
FI (1) FI119678B (no)
NO (1) NO20092433L (no)
RU (1) RU2009124460A (no)
WO (1) WO2008065247A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014201082B2 (en) * 2010-05-24 2015-04-30 Synthetic Biologics, Inc. Modified beta-lactamases and methods and uses related thereto
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
MX352760B (es) 2011-09-09 2017-12-07 Merck Sharp & Dohme Corp Star Metodos para tratar infecciones intrapulmonares.
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
DK2893929T3 (da) 2013-03-15 2025-07-07 Merck Sharp & Dohme Llc Antibiotisk ceftolozansammensætninger
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
BR112016023360B1 (pt) 2014-04-17 2023-03-07 Synthetic Biologics, Inc Beta-lactamase e seu uso
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス，インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
WO2016057744A1 (en) * 2014-10-08 2016-04-14 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
EP3236993B1 (en) 2014-12-23 2023-09-13 Theriva Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
EP3261662B1 (en) 2015-02-23 2021-07-21 Synthetic Biologics Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
EP3265119B1 (en) * 2015-03-06 2023-10-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
CN109562147B (zh) 2016-06-28 2023-09-01 特里瓦生物制剂有限公司 保护微生物组免受口服抗生素
US20190275120A1 (en) * 2016-11-01 2019-09-12 Synthetic Biologics, Inc. Methods and compositions for attenuating antibiotic resistance
CN111511368B (zh) * 2017-12-25 2023-05-09 湘北威尔曼制药股份有限公司 治疗耐药性鲍曼不动杆菌感染的含哌拉西林钠和舒巴坦钠的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
ES2429095T3 (es) * 2005-05-18 2013-11-13 Da Volterra Aporte colónico de adsorbentes

Also Published As

Publication number Publication date
KR20090085122A (ko) 2009-08-06
FI20065757A0 (fi) 2006-11-28
FI20065757L (fi) 2008-05-29
FI119678B (fi) 2009-02-13
EP2086570A1 (en) 2009-08-12
CA2670440A1 (en) 2008-06-05
US20090311234A1 (en) 2009-12-17
CN101563099A (zh) 2009-10-21
JP2010511020A (ja) 2010-04-08
RU2009124460A (ru) 2011-01-10
AU2007327472A1 (en) 2008-06-05
WO2008065247A1 (en) 2008-06-05
BRPI0718880A2 (pt) 2013-12-17

Similar Documents

Publication Publication Date Title
NO20092433L (no) Anvendelse av beta-laktamase
UA101966C2 (xx) Інгібітори бета-лактамаз$ингибиторы бета-лактамаз
ATE509917T1 (de) Gamma-secretase-inhibitoren
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
TN2010000203A1 (en) Beta-lactamase inhibitors
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
GEP20135791B (en) Use of dipeptidyl peptidase inhibitors
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
PH12012500733A1 (en) Methods of administering pirfenidone therapy
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
UA101943C2 (ru) Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
EP1740183B8 (en) Novel use for pde5 inhibitors
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
MX2009006507A (es) Nueva combinacion para usarse en el tratamiento de trastornos inflamatorios.
PH12021551590A1 (en) Quinoline compounds as inhibitors of tam and met kinases
TW200716102A (en) Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
ZA200710497B (en) Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
EA200802136A1 (ru) Лечение меланомы

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application